IP Library Granted Patent US 9,655,850
Granted Patent B2
US 9,655,850 · App. 14/945,168 · Granted May 23, 2017

Substituted diketopiperazine analogs for use as drug delivery agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,655,850
App. No.
14/945,168
Granted
May 23, 2017
Kind
B2
Abstract

Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery.

Claims (19)

1. A method for making a dry powder comprising an active agent, said method comprising: dissolving said active agent in a solution or a suspension comprising a diketopiperazine, and spray drying said solution or suspension to form a dry powder; wherein said diketopiperazine is a substituted diketopiperazine or a the pharmaceutically acceptable salt of said substituted diketopiperazine having the general structure of Formula A:

wherein R is an alkyl group of 1 to 10 carbons or hydrogen; X is an amide bond, an ester, a sulfone, a sulfoxide, an amine, or a ketone; and n or m represents an integer from 0 to 20, and Y is an amide, acid, hydroxyl, phenol, phosphonic acid, or thiol.

2. The method of claim 1 wherein R is hydrogen, n =3, m is C═C, X is —NHC(O)—, and Y is COOH.

3. The method of claim 1 wherein R is hydrogen, n =2, m is C═C, X is —NHC(O)—, and Y is COOH.

4. The method of claim 1 wherein R is an isopropyl, n =3, m is C═C, X is —NHC(O)—, and Y is COOH.

5. The method of claim 1 wherein the active agent is a peptide, protein, polypeptide, small molecule, or nucleic acid molecule.

6. The method of claim 5 , wherein the active agent is selected from the group consisting of insulin, glucagon, glucagon like peptide 1 (GLP-1), calcitonin, parathyroid hormone 1-34, bioactive fragment of parathyroid hormone, octreotide, leuprolide, and RSV peptide, granulocyte colony stimulating factor (GM-CSF), peptide YY, oxyntomodulin, felbamate, cannabinoid antagonists and/or agonists, muscurinic antagonsits and/or agonistics, heparin, low molecular weight heparin, cromolyn, sildenafil, vardenafil, tadalafil, growth hormone, AZT, DDI, lamotrigine, chorionic gonadotropin releasing factor, luteinizing release hormone, β-galactosidase, exendins 1-4, ghrelin, tryptin, and analogs and fragments thereof.

7. The method of claim 5 , wherein the active agent is insulin or an insulin analog.

8. The method of claim 7 wherein the active agent is insulin.

9. The method of claim 8 wherein the insulin is human insulin.

10. The method of claim 5 , wherein the active agent is GLP-1 or a GLP-1 analog.

11. The method of claim 5 , wherein the active agent is oxyntomodulin.

12. A dry powder of claim 1 for delivery to the pulmonary system.

13. The method of claim 5 , wherein the active agent is parathyroid hormone 1-34 or a bioactive fragment thereof.

14. The method of claim 5 wherein the active agent is granulocyte colony stimulating factor.

15. The method of claim 5 , wherein the active agent is vardenafil.

16. The method of claim 5 , wherein the active agent is a cannabinoid antagonist.

17. The method of claim 5 , wherein the active agent is a cannabinoid agonist.

18. The method of claim 5 , wherein the active agent is sildenafil.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded Aug 12, 2025
From: MANNKIND CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 072444/0525 →
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
SECURITY INTEREST Recorded Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2015
From: KRAFT, KELLY SULLIVAN
To: MANNKIND CORPORATION
Reel/Frame 037104/0018 →